Our work focuses on developing novel drugs around kinases, specifically p90 ribosomal S6 kinases (RSK), which we have led the field in establishing as a molecular target for cancer.

Our focus is on treating one of the most aggressive types of breast cancer, triple negative breast cancer (TNBC), which currently does not have any approved targeted treatments.  Our patented cancer compounds position us in the lead to fast track our product to market as it fills an unmet medical need as an effective, safer treatment for a serious medical condition.  Our cancer therapy will potentially save lives and improve the lives of cancer patients.